Shares of SI-BONE, Inc. (NASDAQ:SIBN – Get Free Report) traded up 6.5% during mid-day trading on Wednesday . The company traded as high as $15.11 and last traded at $15.10. 141,538 shares were traded during mid-day trading, a decline of 64% from the average session volume of 398,509 shares. The stock had previously closed at $14.18.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently issued reports on the stock. JMP Securities restated a “market outperform” rating and issued a $32.00 price objective on shares of SI-BONE in a research note on Tuesday, May 7th. Needham & Company LLC dropped their price objective on shares of SI-BONE from $27.00 to $19.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Truist Financial dropped their price objective on shares of SI-BONE from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Finally, Morgan Stanley reduced their target price on SI-BONE from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, SI-BONE has an average rating of “Buy” and a consensus price target of $23.00.
SI-BONE Price Performance
The company has a debt-to-equity ratio of 0.22, a quick ratio of 8.12 and a current ratio of 9.17. The company has a market capitalization of $629.10 million, a price-to-earnings ratio of -13.84 and a beta of 1.20. The company has a 50-day moving average price of $14.13 and a 200-day moving average price of $15.50.
SI-BONE (NASDAQ:SIBN – Get Free Report) last issued its earnings results on Monday, August 5th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.04. The firm had revenue of $39.97 million during the quarter, compared to the consensus estimate of $38.95 million. SI-BONE had a negative net margin of 27.10% and a negative return on equity of 24.27%. During the same quarter in the prior year, the firm earned ($0.30) earnings per share. On average, equities research analysts expect that SI-BONE, Inc. will post -0.89 EPS for the current fiscal year.
Insiders Place Their Bets
In other SI-BONE news, insider Anthony J. Recupero sold 2,087 shares of the stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $14.17, for a total value of $29,572.79. Following the completion of the sale, the insider now directly owns 236,717 shares in the company, valued at $3,354,279.89. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other SI-BONE news, CEO Laura Francis sold 9,967 shares of the stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $13.84, for a total transaction of $137,943.28. Following the completion of the transaction, the chief executive officer now owns 492,923 shares in the company, valued at approximately $6,822,054.32. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Anthony J. Recupero sold 2,087 shares of the business’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $14.17, for a total value of $29,572.79. Following the completion of the sale, the insider now owns 236,717 shares in the company, valued at $3,354,279.89. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 23,950 shares of company stock worth $329,060. Corporate insiders own 5.40% of the company’s stock.
Hedge Funds Weigh In On SI-BONE
A number of large investors have recently bought and sold shares of SIBN. Granahan Investment Management LLC lifted its position in shares of SI-BONE by 13.2% in the fourth quarter. Granahan Investment Management LLC now owns 1,286,450 shares of the company’s stock worth $27,003,000 after purchasing an additional 150,217 shares in the last quarter. Bullseye Asset Management LLC boosted its stake in shares of SI-BONE by 218.6% during the 4th quarter. Bullseye Asset Management LLC now owns 102,024 shares of the company’s stock worth $2,141,000 after buying an additional 70,000 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of SI-BONE by 34.9% in the 4th quarter. Wellington Management Group LLP now owns 817,048 shares of the company’s stock valued at $17,150,000 after acquiring an additional 211,209 shares in the last quarter. Bellevue Group AG acquired a new stake in shares of SI-BONE in the fourth quarter valued at about $2,628,000. Finally, Champlain Investment Partners LLC increased its position in shares of SI-BONE by 104.8% in the first quarter. Champlain Investment Partners LLC now owns 2,453,147 shares of the company’s stock valued at $40,158,000 after acquiring an additional 1,255,610 shares during the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.
SI-BONE Company Profile
SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.